Analysis of Gal-3 expression across multiple RNA sequencing public datasets, combined with data from the GEPIA website, revealed significantly elevated RNA expression levels of Gal-3 in various tumor types, including colon cancer, diffuse large B-cell lymphoma, glioma, kidney cancer, liver cancer, pancreatic cancer, rectal adenocarcinoma, thyroid cancer, gastric cancer, and thymoma, compared with normal tissues (Fig. 1A). Here, LGALS3 is linked to glioma.